This is one of the reasons why an ever-increasing number of people *do not* trust these pro-pharma studies. There were two terrible flaws that rendered this meta analysis useless:
1. Rather than doing sero-prevalence testing to include *all* persons with COVID, including the vast majority of people who had COVID without symptoms or with mild symptoms, they only included persons who were sick enough to seek medical attention. On the other hand, the population of the vaccinated included everyone, even those who were not yet sick after what was, in some cases, a short followup (e.g., 7 days).
Whenever you compare a population of healthy+not yet sick+sick (vaccinated) to only those seeking medical attention (COVID+), you automatically and drastically skew the results. For example, if 5 in 10 million cases of COVID+ resulted in myocarditis, that might be a low rate. But if you then create a study that only looks at the sick individuals, you might have a rate of 5 cases of myocarditis in 200,000 cases of COVID+ seeking medical attention. That is how you make the rate of myocarditis with COVID+ appear much higher.
2. They combined all age groups rather than looking at the age groups most at risk.
Prasad looked at the most at risk age groups as well as the risk of more than just a single injection of vaccine drugs. See chart below. The pink bar on the right is the over-estimation of the rate of myocarditis due to COVID when primarily looking at persons seeking medical attention.
This information was published in the European Journal of Clinical Investigation:
It should be noted that in 2021 Prasad mentioned that the only way to accurately compare myocarditis rates in those injected with vaccine drugs to those who had COVID was to do sero-prevalence tests to include the entire population who had COVID and then focus on the at-risk age groups. Prasad also separated out various vaccine drug brands as well as how many shots were given.
I always return to relying on independent researchers as the best source of information. Look at the analysis of a wide variety of independent researchers is the best way to go, IMO.